New York State Common Retirement Fund Acquires 188,347 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

New York State Common Retirement Fund increased its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 1,475.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 201,112 shares of the specialty pharmaceutical company's stock after acquiring an additional 188,347 shares during the quarter. New York State Common Retirement Fund owned about 0.62% of Collegium Pharmaceutical worth $6,190,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in COLL. China Universal Asset Management Co. Ltd. lifted its position in shares of Collegium Pharmaceutical by 320.0% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,776 shares of the specialty pharmaceutical company's stock worth $116,000 after purchasing an additional 2,877 shares during the period. Versor Investments LP bought a new stake in Collegium Pharmaceutical during the third quarter valued at $207,000. SG Americas Securities LLC acquired a new stake in Collegium Pharmaceutical during the 3rd quarter worth about $221,000. O Shaughnessy Asset Management LLC raised its position in shares of Collegium Pharmaceutical by 14.3% in the 3rd quarter. O Shaughnessy Asset Management LLC now owns 11,509 shares of the specialty pharmaceutical company's stock worth $257,000 after acquiring an additional 1,440 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Collegium Pharmaceutical by 28.6% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,841 shares of the specialty pharmaceutical company's stock valued at $272,000 after purchasing an additional 1,967 shares during the period.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on COLL shares. Truist Financial lifted their target price on Collegium Pharmaceutical from $37.00 to $40.00 and gave the stock a "buy" rating in a report on Monday, February 26th. Needham & Company LLC reiterated a "buy" rating and set a $40.00 target price on shares of Collegium Pharmaceutical in a research report on Thursday, April 11th. Piper Sandler restated an "overweight" rating and issued a $39.00 price target (up from $37.00) on shares of Collegium Pharmaceutical in a report on Friday, February 23rd. Finally, StockNews.com lowered shares of Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a report on Wednesday. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $39.00.

Collegium Pharmaceutical Price Performance

Collegium Pharmaceutical stock remained flat at $37.51 during mid-day trading on Friday. The company had a trading volume of 300,393 shares, compared to its average volume of 332,726. Collegium Pharmaceutical, Inc. has a 1-year low of $20.83 and a 1-year high of $40.95. The company has a market capitalization of $1.23 billion, a price-to-earnings ratio of 31.79 and a beta of 1.06. The business has a 50 day simple moving average of $37.56 and a two-hundred day simple moving average of $31.84. The company has a debt-to-equity ratio of 2.48, a current ratio of 1.17 and a quick ratio of 1.10.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last issued its quarterly earnings results on Thursday, February 22nd. The specialty pharmaceutical company reported $1.45 EPS for the quarter, beating analysts' consensus estimates of $1.20 by $0.25. Collegium Pharmaceutical had a return on equity of 107.39% and a net margin of 8.50%. The firm had revenue of $149.75 million for the quarter, compared to analysts' expectations of $147.66 million. On average, sell-side analysts forecast that Collegium Pharmaceutical, Inc. will post 5.63 earnings per share for the current year.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.